Skip to content

Comparison the effects of calcitonin mesotherapy and steroid injection in patients with lumbar spinal canal stenosis

Comparison the effect of calcitonin mesotherapy vs. methylprednisolone acetate injection in lumbar canal stenosis patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240914063037N1
Enrollment
54
Registered
2024-10-09
Start date
2024-10-12
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lumbar spinal canal stenosis. Spinal stenosis, lumbar region

Interventions

Intervention 1: Intervention group: Injection of calcitonin by mesotherapy in DU-2, DU-6, bilateral BL-50 & BL-52 acupoints. Intervention 2: Intervention group: Methylprednisolone acetate injection in

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Completing and signing the informed consent form The diagnosis of spinal canal stenosis has been confirmed by radiography, MRI or electrodiagnosis having at least 6 months of clinical symptoms of spinal cord stenosis (back pain, lameness, radicular leg pain,...)

Exclusion criteria

Exclusion criteria: Uncontrolled diabetes Rheumatologic or collagen vascular diseases Melignancy Severe liver, kidney, heart or lung disease Coagulation disorders History of anti-coagulation medication concumption Brucellosis infection History of spinal canal surgery Suffering from concurrent diabetic neuropathy or radiculopathy Body mass index above 24 History of allergic reaction to the medications used in the study Inability to communicate and complete the questionnaire History of methylprednisolone acetate or calcitonin injection in the last three months

Design outcomes

Primary

MeasureTime frame
Pain reduction, Functional improvement. Timepoint: Before starting treatment and 4 and 8 weeks after the injection. Method of measurement: Visual Analogue Scale of Pain, Shortform-36 health survey, Quebec Back Pain Disability Scale.

Secondary

MeasureTime frame
Hopping ability. Timepoint: Before starting treatment and 4 and 8 weeks after injection. Method of measurement: Standard Hopping Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyedeh Niloofar Sepehrtaj

Shiraz University of Medical Sciences

nsepehrtaj@sums.ac.ir+98 71 3231 9040

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026